# A Phase II Study Evaluating Intravenous Melphalan With Autologous Whole Blood Stem Cell Transplantation Over Three Cycles In Patients With Castration-Resistant Prostate Cancer (MEL-CAP)

> **NCT01907009** · PHASE2,PHASE3 · TERMINATED · sponsor: **Barts & The London NHS Trust** · enrollment: 29 (actual)

## Conditions studied

- Castrate Resistant Prostate Cancer

## Interventions

- **DRUG:** Melphalan
- **DRUG:** Lenograstim

## Key facts

- **NCT ID:** NCT01907009
- **Lead sponsor:** Barts & The London NHS Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-01
- **Primary completion:** 2016-12-22
- **Final completion:** 2016-12-22
- **Target enrollment:** 29 (ACTUAL)
- **Why stopped:** Early termination
- **Last updated:** 2023-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01907009

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01907009, "A Phase II Study Evaluating Intravenous Melphalan With Autologous Whole Blood Stem Cell Transplantation Over Three Cycles In Patients With Castration-Resistant Prostate Cancer (MEL-CAP)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01907009. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*